Circulating cytokines and angiogenic factors based signature associated with the relative dose intensity during treatment in patients with advanced hepatocellular carcinoma receiving lenvatinib

Atsushi Ono,Hiroshi Aikata,Masami Yamauchi,Kenichiro Kodama,Waka Ohishi,Takeshi Kishi,Kazuki Ohya,Yuji Teraoka,Mitsutaka Osawa,Hatsue Fujino,Takashi Nakahara,Eisuke Murakami,Daiki Miki,Tomokazu Kawaoka,Hiromi Abe-Chayama,Peiyi Zhang,Songyao Liu,Grace Naswa Makokha,Masataka Tsuge,Michio Imamura,C. Nelson Hayes,Kazuaki Chayama

Circulating cytokines and angiogenic factors based signature associated with the relative dose intensity during treatment in patients with advanced hepatocellular carcinoma receiving lenvatinib

2020

Background:Although lenvatinib was recently approved for treatment of advanced unresectable hepatocellular carcinoma (HCC) based on the phase III REFLECT trial, no biomarkers for management of lenv...

Keywords:

dose intensity
Internal medicine
Oncology
Lenvatinib
Medicine
Hepatocellular carcinoma
Biomarker (medicine)
Pathology
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations